3 trial readouts that could shake up the obesity market this year

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

PharmaVoice’s Crystal Ball: The industry’s AI future

How AI will further transform the business of drug discovery and development in 2025.

Subcutaneous options offer convenience for patients — and a valuable window for drugmakers

New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.

4 closely watched FDA approval dates in 2025 from J&J, Novo and more

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.

PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?

How regulators could hit PBMs from multiple sides in the coming year.

How pharma was instrumental in President Jimmy Carter’s global health efforts

Pharma companies stepped up to support The Carter Center and provide access to life-saving treatments.

FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end of recent annual tallies.

4 companies to watch in the accelerating gene editing race

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

Zepbound, Mounjaro shortages are resolved, FDA confirms

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

Merck’s RSV antibody could soon paddle into the rough waters of a crowded market

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

Big Pharma’s new DTC play: partnering with digital health providers

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.

A biotech’s race to tackle the most severe hepatitis

Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.

3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

Oncology, obesity and more: Where pharma R&D is headed in 2025

With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.  

Will the ‘anti-woke’ movement derail DEI efforts in pharma?

Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases. 

GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?

The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.

Endometriosis drug research, long underfunded, confronts familiar problems in women’s health

Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.

What’s next for 23andMe?

Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.

GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide.

Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide

Leading companies in the psychedelics space have had trouble crossing the regulatory threshold. Here’s where they’re going wrong — and how to fix it.

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.

Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready?

The push to bring generic drug production back home has failed to reach a critical mass.